VEGFA and glioblastoma: However, recent phase III trials in newly diagnosed glioblastoma demonstrated a failure of the monoclonal anti-VEGF-directed antibody bevacizumab (BEV) to extend overall survival (OS) when combined with chemoradiation, despite benefits in progression-free survival (PFS) and quality of life [2, 3].